Canada - English - Health Canada

apotex inc - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 5mg - tacrolimus (tacrolimus monohydrate) 5mg - immunosuppressive agents

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 2.044 mg (equivalent: tacrolimus, qty 2 mg) - capsule - excipient ingredients: hypromellose; croscarmellose sodium; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; brilliant blue fcf; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 0.767 mg (equivalent: tacrolimus, qty 0.75 mg) - capsule - excipient ingredients: hypromellose; croscarmellose sodium; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 0.767mg equivalent to 0.75mg tacrolimus - capsule - 0.75 mg - active: tacrolimus monohydrate 0.767mg equivalent to 0.75mg tacrolimus excipient: brilliant blue fcf   croscarmellose sodium ethanol gelatin   hypromellose iron oxide yellow   lactose monohydrate magnesium stearate titanium dioxide   - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 2.044mg equivalent to 0.2mg tacrolimus - capsule - 2 mg - active: tacrolimus monohydrate 2.044mg equivalent to 0.2mg tacrolimus excipient: brilliant blue fcf   croscarmellose sodium ethanol gelatin   hypromellose iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate titanium dioxide   - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

Canada - English - Health Canada

jamp pharma corporation - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 1mg - tacrolimus (tacrolimus monohydrate) 1mg - immunosuppressive agents

Canada - English - Health Canada

jamp pharma corporation - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 5mg - tacrolimus (tacrolimus monohydrate) 5mg - immunosuppressive agents

Canada - English - Health Canada

accord healthcare inc - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 1mg - tacrolimus (tacrolimus monohydrate) 1mg - immunosuppressive agents

Canada - English - Health Canada

accord healthcare inc - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 5mg - tacrolimus (tacrolimus monohydrate) 5mg - immunosuppressive agents

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 1.022mg equivalent to 1 mg tacrolimus - capsule - 1 mg - active: tacrolimus monohydrate 1.022mg equivalent to 1 mg tacrolimus excipient: croscarmellose sodium hypromellose capsugel white/brown g4ics000510 lactose monohydrate magnesium stearate - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidneys) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.